advertising
-
1
Nicolau DP, Stein GE: Therapeutic options for diabetic foot infections: a review with an emphasis on tissue penetration characteristics. JAPMA 100: 52, 2010.
-
2
Lipsky BA, Berendt AR, Cornia PB, et al: 2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections. Clin Infect Dis 54: 132, 2012.
-
3
Mueller M, dela Pena A, Derendorf H: Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother 48: 1441, 2004.
-
4
Eleftheriadou I, Tentolouris N, Argiana V, et al: Methicillin-resistant Staphylococcus aureus in diabetic foot infections. Drugs 70: 1785, 2010.
-
5
Citron DM, Goldstein EJC, Merriam CV, et al: Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 45: 2819, 2007.
-
6
Craig WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26: 1, 1998.
-
7
Schmidt S, Banks R, Kumar V, et al: Clinical microdialysis in skin and soft tissues: an update. J Clin Pharmacol 48: 351, 2008.
-
8
Beran T: Pharmacokinetics of tissue penetration of antibiotics. Rev Infect Dis 3: 45, 1981.
-
9
Bhalodi AA, Housman ST, Shepard A, et al: Tissue pharmacokinetics of cefazolin in patients with lower limb infections. Antimicrob Agents Chemother 57: 5679, 2013.
-
10
Legat FJ, Krause R, Zenahlik P, et al: Penetration of piperacillin and tazobactam into inflamed soft tissue of patients with diabetic foot infection. Antimicrob Agents Chemother 49: 4368, 2005.
-
11
Craig WA: Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin N Am 17: 479, 2003.
-
12
Wise R, Logan M, Cooper M, et al: Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother 35: 1081, 1991.
-
13
Burkhardt O, Brunner M, Schmidt S, et al: Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J Antimicrob Chemother 58: 632, 2006.
-
14
Mouton JW, Touzw DJ, Horrevorts AM, et al: Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 39: 185, 2000.
-
15
Livermore DM, Carter MW, Bagel S, et al: In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 45: 1860, 2001.
-
16
Fuchs PC, Barry AL, Brown SD: In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother 45: 1915, 2001.
-
17
Livermore DM, Oakton KJ, Carter MW, et al: Activity of eratapenem (MK-0826) versus Enterobacteriaceae with potent β-lactamases. Antimicrob Agents Chemother 45: 2831, 2001.
-
18
Laethem T, Lepeleire ID, McCrea J, et al: Tissue penetration by ertapenem, a parenteral carbapenem administerd once daily, in suction-induced skin blister fluid in healthy young volunteers. Antimicrob Agents Chemother 47: 1439, 2003.
-
19
Skhirtladze K, Hutschala D, Fleck T, et al: Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 50: 1372, 2006.
-
20
Housman ST, Bhalodi AA, Shepard A, et al: Vancomycin tissue pharmacokinetics in patients with lower limb infections via in vivo microdialysis. JAPMA 105: 381, 2015.
-
21
Zhanel GG, Adam HJ, Baxter MR, et al: Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. J Antimicrob Chemother 68 (suppl 1): i7, 2013.
-
22
Sader HS, Flamm RK, Jones RN: Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). Diagn Microbiol Infect Dis 76: 61, 2013.
-
23
Wiskirchen DE, Shepard A, Kuti JL, et al: Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis. Antimicrob Agents Chemother 55: 4170, 2011.
-
24
Andes D, van Ogtrop ML, Peng J, et al: In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 46: 3484, 2002.
-
25
Rayner CR, Forrest A, Meagher AK, et al: Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 15: 1411, 2003.
-
26
Farrell DJ, Mendes RE, Ross JE, et al: Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagn Microbiol Infect Dis 65: 392, 2009.
-
27
Gee T, Ellis R, Marshall G, et al: Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 45: 1843, 2001.
-
28
Kim A, Suecof LA, Sutherland CA, et al: In vivo microdialysis study of penetration of daptomycin into soft tissues in diabetic versus healthy volunteers. Antimicrob Agents Chemother 52: 3941, 2008.
-
29
Traunmueller F, Schintler MV, Metzler J, et al: Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother 65: 1252, 2010.
-
30
Safdar N, Andes D, Craig WA: In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 48: 63, 2004.
-
31
Sader HS, Jones RN: Antimicrobial susceptibility of gram-positive bacteria isolated from US medical centers: results of the daptomycin surveillance program (2007-2008). Diag Microbiol Infect Dis 65: 158, 2009.
-
32
Wise R, Gee T, Andrews JM, et al: Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother 46: 31, 2002.
-
33
Brunner M, Hollenstein U, Delacher S, et al: Distribution and antimicrobial activity of ciprofloxacin in human soft tissues. Antimicrob Agents Chemother 43: 1307, 1999.
-
34
Brunner M, Stass H, Moeller JG, et al: Target site concentrations of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 46: 3724, 2002.
-
35
Mueller M, Brunner M, Hollenstein U, et al: Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients. Antimicrob Agents Chemother 43: 2056, 1999.
-
36
Lubowski TJ, Nightingale C, Sweeney K, et al: Penetration of fleroxacin and ciprofloxacin into skin blister fluid: a comparative study. Antimicrob Agents Chemother 36: 651, 1992.
-
37
Forrest A: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37: 1073, 1993.
-
38
Clinical Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing; 23rd Informational Supplement. Clinical Laboratory Standards Institute, Wayne, PA, 2013. CLSI M100-S23.
-
39
Bulik CC, Wiskirchen DE, Shapard A, et al: Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. Antimicrob Agents Chemother 54: 5209, 2010.
-
40
Dowzicky MJ, Park CH: Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Clin Ther 30: 2040, 2008.
-
41
Crandon JL, Banevicius MA, Nicolau DP: Pharmacodynamic of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. Antimicrob Agents Chemother 53: 1165, 2009.
-
42
Sun HK, Ong CT, Umer A, et al: Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 49: 1629, 2005.
-
43
Mueller M: Science, medicine, and the future: microdialysis. BMJ 324: 588, 2002.
-
44
Chaurasia CS, Mueller M, Bashaw ED, et al: AAPS-FDA workshop white paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol 47: 589, 2007.
-
45
Mueller M, Haag O, Burgdorff T, et al: Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans. Antimicrob Agents Chemother 40: 2703, 1996.
-
46
Douglas A, Udy AA, Wallis SC, et al: Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery. Antimicrob Agents Chemother 55: 5238, 2011.
-
47
Dalla Costa Q, Nolting A, Kovar A, et al: Determination of free concentration of piperacillin-tazobactam combinations by microdialysis. J Antimicrob Chemother 42: 769, 1998.
-
48
Tomaselli F, Dittrich P, Maier A, et al: Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis. Br J Clin Pharmacol 50: 620, 2003.
-
49
Buerger C, Plock N, Dehghanyar P, et al: Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother 50: 2455, 2006.
-
50
Dehghanyar P, Buerger C, Zeitlinger M, et al: Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother 49: 2367, 2005.
-
51
Koomanachai P, Keel RA, Johnson-Arbor KK, et al: Linezolid penetration into wound tissue of two diabetic patients before and after hyperbaric oxygen therapy. Undersea Hyperb Med 38: 11, 2011.
-
52
Traunmuller F, Schintler MV, Spendel S, et al: Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections. Int J Antimicrob Agents 36: 84, 2010.
-
53
Keel RA, Crandon JL, Nicolau DP, et al: Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions. Antimicrob Agents Chemother 56: 3420, 2012.
-
54
Kuti JL, Nicolau DP: Levofloxacin penetration into epithelial lining fluid differs between infected and uninfected patients. Paper presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 9-12, 2012, San Francisco, CA. Abstract A-1964.
-
55
Arcieri G, August R, Becker N, et al: Clinical experience with ciprofloxacin in the USA. Eur J Clin Microbiol 5: 220, 1986.
-
56
Daschner FD, Westenfelder M, Dalhoff A: Penetration of ciprofloxacin into kidney, fat, muscle and skin tissue. Eur J Clin Microbiol 5: 212, 1986.
-
57
Licitra CM, Brooks RG, Sieger BE: Clinical efficacy and levels of ciprofloxacin in tissue in patients with soft tissue infection. Antimicrob Agents Chemother 31: 805, 1987.
-
58
Capecchi PL, Blardi P, De Lalla A, et al: Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. Clin Pharmacol 57: 446, 1995.
Antibiotic Tissue Penetration in Diabetic Foot Infections
A Review of the Microdialysis Literature and Needs for Future Research
Search for other papers by Amanda Ray in
Current site
Google Scholar
PubMed
Search for other papers by Danielle Malin in
Current site
Google Scholar
PubMed
Division of Infectious Diseases, Hartford Hospital, Hartford, CT.
Search for other papers by David P. Nicolau in
Current site
Google Scholar
PubMed
Department of Pharmacy, Saint Francis Hospital and Medical Center, Hartford, CT.
Search for other papers by Dora E. Wiskirchen in
Current site
Google Scholar
PubMed
Although many antimicrobial agents display good in vitro activity against the pathogens frequently implicated in diabetic foot infections, effective treatment can be complicated by reduced tissue penetration in this population secondary to peripheral arterial disease and emerging antimicrobial resistance, which can result in clinical failure. Improved characterization of antibiotic tissue pharmacokinetics and penetration ratios in diabetic foot infections is needed. Microdialysis offers advantages over the skin blister and tissue homogenate studies historically used to define antibiotic penetration in skin and soft-tissue infections by defining antibiotic penetration into the interstitial fluid over the entire concentration versus time profile. However, only a select number of agents currently recommended for treating diabetic foot infections have been evaluated using these methods, which are described herein. Better characterization of the tissue penetration of antibiotic agents is needed for the development of methods for maximizing the pharmacodynamic profile of these agents to ultimately improve treatment outcomes for patients with diabetic foot infections.
advertising
